Literature DB >> 11413124

Recurrent Clostridium difficile diarrhoea.

L Kyne1, C P Kelly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11413124      PMCID： PMC1728368          DOI： 10.1136/gut.49.1.152

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

Review 1.  Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee.

Authors:  R Fekety
Journal:  Am J Gastroenterol       Date:  1997-05       Impact factor: 10.864

Review 2.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

3.  Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis.

Authors:  F J Tedesco; D Gordon; W C Fortson
Journal:  Am J Gastroenterol       Date:  1985-11       Impact factor: 10.864

4.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

5.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

6.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

Authors:  L V McFarland; C M Surawicz; R N Greenberg; R Fekety; G W Elmer; K A Moyer; S A Melcher; K E Bowen; J L Cox; Z Noorani
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

7.  Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.

Authors:  D Y Leung; C P Kelly; M Boguniewicz; C Pothoulakis; J T LaMont; A Flores
Journal:  J Pediatr       Date:  1991-04       Impact factor: 4.406

8.  Prospects for a vaccine for Clostridium difficile.

Authors:  L Kyne; C P Kelly
Journal:  BioDrugs       Date:  1998-09       Impact factor: 5.807

9.  Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin.

Authors:  B P Buggy; R Fekety; J Silva
Journal:  J Clin Gastroenterol       Date:  1987-04       Impact factor: 3.062

10.  Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991.

Authors:  M M Olson; C J Shanholtzer; J T Lee; D N Gerding
Journal:  Infect Control Hosp Epidemiol       Date:  1994-06       Impact factor: 3.254
  10 in total
  18 in total

1.  Clostridium difficile colitis in children with cystic fibrosis.

Authors:  Sunny Zaheed Hussain; Cathy Chu; David P Greenberg; David Orenstein; Seema Khan
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

2.  Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection.

Authors:  Fnu Rafiullah; Sunil Kanwal; Usman M Majeed; Mark A Korsten; Faisal H Cheema; Munish Luthra; Muhammad Rizwan Sohail
Journal:  BMJ Case Rep       Date:  2011-11-21

3.  Role of the global regulator Rex in control of NAD+ -regeneration in Clostridioides (Clostridium) difficile.

Authors:  Laurent Bouillaut; Thomas Dubois; Michael B Francis; Nadine Daou; Marc Monot; Joseph A Sorg; Abraham L Sonenshein; Bruno Dupuy
Journal:  Mol Microbiol       Date:  2019-04-02       Impact factor: 3.501

4.  Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis.

Authors:  Palna Mehta; Ronald G Nahass; Luigi Brunetti
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

5.  Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea.

Authors:  Ji Won Kim; Kook Lae Lee; Ji Bong Jeong; Byeong Gwan Kim; Sue Shin; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  World J Gastroenterol       Date:  2010-07-28       Impact factor: 5.742

6.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 7.  Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy.

Authors:  Munshi Moyenuddin; John C Williamson; Christopher A Ohl
Journal:  Curr Gastroenterol Rep       Date:  2002-08

8.  Clinical predictors of recurrent Clostridium difficile infection in out-patients.

Authors:  R Shivashankar; S Khanna; P P Kammer; W Scott Harmsen; A R Zinsmeister; L M Baddour; D S Pardi
Journal:  Aliment Pharmacol Ther       Date:  2014-07-10       Impact factor: 8.171

Review 9.  Clostridium difficile associated infection, diarrhea and colitis.

Authors:  Perry Hookman; Jamie S Barkin
Journal:  World J Gastroenterol       Date:  2009-04-07       Impact factor: 5.742

10.  Metronidazole resistance in Clostridium difficile is heterogeneous.

Authors:  T Peláez; E Cercenado; L Alcalá; M Marín; A Martín-López; J Martínez-Alarcón; P Catalán; M Sánchez-Somolinos; E Bouza
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.